National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Exviera® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults. Exviera® must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera® combination therapy are viekirax® or viekirax®   and ribavirin.

 

Viekirax® is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (CHC) in adults viekirax® must not be administered as monotherapy. Depending on the patient population, the recommended co-administered medicinal products for viekirax® are exviera® or exviera® and ribavirin or ribavirin.

 

Rapid Review

Commenced Completed Outcome
21/12/2014 13/01/2015 Full Pharmacoeconomic Evaluation Recommended

 

Pharmacoeconomic Evaluation

Commenced Completed Outcome
15/01/2015 10/02/2016 Reimbursement recommended in certain sub-populations of patients with genotype 1 & 4.

Summary